34. TARGETED THERAPY FOR HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS

INTRO: One in three women with HER2-positive breast cancer will develop brain metastases, or intracranial metastatic disease (IMD). Historically, treatment of IMD has been confined to surgery and radiotherapy, with a limited role for chemotherapy. However, recent interest has burgeoned in a role for...

Descripción completa

Detalles Bibliográficos
Autores principales: Erickson, Anders, Ghodrati, Farinaz, Das, Sunit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401393/
http://dx.doi.org/10.1093/noajnl/vdaa073.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401393/
http://dx.doi.org/10.1093/noajnl/vdaa073.022

Ejemplares similares